• KOL
    • Ovarian Stimulation
    • Bart C J M Fauser
    • Bart C J M FAUSER: Influence Statistics

      Bart C J M FAUSER

      Bart C J M FAUSER

      Show email address

      University of Utrecht, Utrecht, the Netherlands. | University Medical Center, 3584 Utrecht, the Netherlands. | University of Utrecht, Utrecht, The Netherlands | Department of ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Bart C J M FAUSER:Expert Impact

      Concepts for whichBart C J M FAUSERhas direct influence:Ovarian stimulation,Polycystic ovary syndrome,Vitro fertilization,Ovulation induction,Polycystic ovary,Ovary syndrome,Ovarian reserve,Women pcos.

      Bart C J M FAUSER:KOL impact

      Concepts related to the work of other authors for whichfor which Bart C J M FAUSER has influence:Polycystic ovary syndrome,Ovarian reserve,Women pcos,Vitro fertilization,Live birth,Ovulation induction,Insulin resistance.

      KOL Resume for Bart C J M FAUSER

      Year
      2021

      University of Utrecht, Utrecht, the Netherlands.

      2020

      University of Utrecht, Utrecht, The Netherlands

      2019

      Department of Reproductive Medicine & Gynecology University Medical Center Utrecht, University of Utrecht Utrecht the Netherlands

      2018

      Wilhelmina Children’s Hospital Birth Center (G.A.Z., B.B.v.R., A.F.) Department of Reproductive Medicine and Gynaecology (B.C.J.M.G.) Julius Center for Health Sciences and Primary Care (Y.v.d.G.) Department of Vascular Medicine (F.L.V.) Department of Radiology (B.K.V.), University Medical Center Utrecht, Netherlands Department of Obstetrics and Gynaecology (L.B., E.A.P.S.) Department of Cardiology (E.B., R.P.J.B.) Department of Radiology (R.P.J.B.) Department of Internal Medicine (J.E.R.v.L.), Erasmus Medical Center, Rotterdam, Netherlands Department of Obstetrics and Gynecology, VU University Medical Center, Amsterdam, Netherlands (G.J.M.d.G.) Department of Cardiology, Radboud University Medical Center, Nijmegen, Netherlands (A.H.E.M.M.) Academic Unit of Human Development and Health, University of Southampton, Southampton, United Kingdom (B.B.v.R.).

      Department of Reproductive Medicine and Gynaecology, University Medical Center Utrecht, Utrecht, The Netherlands.

      Chief Editor RBMO

      2017

      University Medical Center, Utrecht, Utrecht, Netherlands

      2016

      Department of Reproductive Medicine and Gynecology (N.M.P.D., M.P.H.K., B.C.J.M.F.), University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands; Department of Epidemiology (T.M., O.H.F., M.K.), Erasmus MC, University Medical Center Rotterdam, 3015 CE Rotterdam, The Netherlands; Department of Internal Medicine (J.E.R.v.L.), Division Vascular Medicine, Erasmus Medical Center Rotterdam, 3015 CE Rotterdam, The Netherlands; Department of Obstetrics and Gynecology (C.B.L.), VU University Medical Center Amsterdam, 1081 HV Amsterdam, The Netherlands; Department of Obstetrics and Gynecology (J.S.E.L., C.M.), Erasmus MC, University Medical Center Rotterdam, 3015 CE Rotterdam, The Netherlands; Department of Cardiology (C.G.K.M.F.), University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands; Department of Clinical Chemistry (Y.B.d.R.), Erasmus MC, University Medical Center Rotterdam, 3015 CE Rotterdam, The Netherlands; and Department of Cardiology (E.B.), Erasmus MC, University Medical Center Rotterdam, Cardiovascular Research School Erasmus University Rotterdam, 3015 CE Rotterdam, The Netherlands.

      Division Woman & Baby, University Medical Center Utrecht, Utrecht, the Netherlands

      Director of Research and Physician-in-Chief Emeritus, Harvard Medical School, Boston, Massachusetts

      Robert G. Dunlop Professor of Medicine Dean, Raymond and Ruth Perelman School of Medicine Executive Vice President University of Pennsylvania for the Health System Philadelphia, Pennsylvania

      Sir John Monadh Distinguished Professor, Monash University, Melbourne, Australia

      2015

      Department of Reproductive Medicine & Gynecology University Medical Center Utrecht, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, Netherlands

      2014

      University Pierre et Marie Curie Paris, France University Medical Center Utrecht Utrecht, The Netherlands.

      Executive Vice President for Medical Affairs, VCU Health System

      Kate Macy Ladd Professor, Department of Obstetrics, Gynecology, and Reproductive Biology, Harvard Medical School

      Chair, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital, Boston, Massachusetts

      2013

      Division of Woman & Baby, Department of Reproductive Medicine & Gynaecology, University Medical Centre, Utrecht, TheNetherlands

      Department of Reproductive Medicine and Gynaecology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands

      2012

      Division of Reproductive Medicine (F.J.B., B.C.J.M.F.), Department of Reproductive Medicine and Gynecology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands

      Direttore Scientifico S.I.S.Me.R., Coordinatore Endocrinologia Ginecologica S.I.S.Me.R., S.I.S.Me.R., Via Mazzini 12, 40138 Bologna, Italy

      2011

      University Medical Center, Utrecht, the Netherlands

      2010

      Department of Reproductive Medicine and Gynecology, University Medical Center, room F05.126, P.O. Box 85500, 3508 GA Utrecht, The Netherlands

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Bart C J M FAUSER is among the top experts in the world.
      Concept World rank
      iu concentrations #1
      nr5a1 gene women #1
      stepdown cycles #1
      ovarian responsiveness fsh #1
      clinical conditions lcms #1
      dhea cocs #1
      levels ovarian #1
      normogonadotropic clomiphene #1
      aneuploid blastomeres compaction #1
      rotterdam consensus criteria #1
      blastocysts rhfsh dose #1
      sexual function ocs #1
      pcos opcos #1
      metabolic consequences new #1
      2 women age #1
      classical ovulation #1
      aneuploidy mosaicism embryos #1
      ovarian ageing women #1
      stimulation follicle development #1
      assistedconception #1
      ivf mild #1
      spontaneous diabetes birth #1
      fsh poi #1
      follicle growth disruption #1
      implementation cvd screening #1
      early cessation gnrha #1
      finally cancer risk #1
      gonadotropin induction #1
      sex steroids endometrium #1
      cpc somatic cells #1
      pcos obstetric diabetes #1
      30 17ohp #1
      cpc human zygotes #1
      idiopathic oligozoospermia levels #1
      gonadotropindeficient #1
      stimulation day alfa #1
      ocplacebo #1
      121 μg #1
      absent correlation #1
      total ocp #1
      stroma echogenicity #1
      fsh wmd #1
      transferred embryos predictors #1
      immunoreactive fsh oligospermia #1
      pill free #1
      female testosterone dhea #1
      iu ovulation induction #1
      cumulative singleton #1
      5 upa #1
      fsh bioassays #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Bart C J M FAUSER

      KOL-Index: 26172

      STUDY QUESTION: What is the recommended assessment and management of women with polycystic ovary syndrome (PCOS), based on the best available evidence, clinical expertise and consumer preference?

      SUMMARY ANSWER: International evidence-based guidelines, including 166 recommendations and practice points, addressed prioritized questions to promote consistent, evidence-based care and improve the experience and health outcomes of women with PCOS.

      WHAT IS KNOWN ALREADY: Previous guidelines ...

      Known for Based Guideline | International Evidence | Management Pcos | Recommendations Assessment | Polycystic Ovary
      KOL-Index: 20768

      Importance: As many as 10% of women experience natural menopause by the age of 45 years. If confirmed, an increased risk of cardiovascular disease (CVD) and all-cause mortality associated with premature and early-onset menopause could be an important factor affecting risk of disease and mortality among middle-aged and older women.

      Objective: To systematically review and meta-analyze studies evaluating the effect of age at onset of menopause and duration since onset of menopause on ...

      Known for Cardiovascular Outcomes | Menopause Onset | Cvd Mortality | Chd Stroke | Risk Disease
      KOL-Index: 18743

      Extending the FSH window for multifollicular development by administering FSH from the midfollicular phase onward constitutes a novel mild protocol for ovarian stimulation for in vitro fertilization (IVF) based on the physiology of single dominant follicle selection in normo-ovulatory women. We compared outcomes from this protocol with two other stimulation protocols. One hundred and forty-two normo-ovulatory patients with an indication for IVF (or IVF/ICSI) were randomized to a GnRH ...

      Known for Ovarian Stimulation | Cycle Day | Recombinant Follicle | Antagonist Cotreatment | Randomized Comparison
      KOL-Index: 18628

      STUDY QUESTION: Are fragile X mental retardation gene 1 (FMR1) CGG repeats in the normal and intermediate range (up to 55 repeats) associated with primary ovarian insufficiency (POI) in a large case-control study?

      SUMMARY ANSWER: No association was found between CGG repeats of intermediate size and POI compared with controls.

      WHAT IS KNOWN ALREADY: CGG repeats in the FMR1 gene in the premutation range (55-200 repeats) have consistenly associated with POI. Intermediate range CGG repeats ...

      Known for Cgg Repeat | Primary Ovarian Insufficiency | Women Poi | Mental Retardation | Intermediate Range
      KOL-Index: 18467

      Insulin-like growth factors (IGFs) and their binding proteins (IGFBPs) have important regulatory functions in ovarian follicular development. Although most studies have investigated the IGF system in ovarian cells in vitro, investigation of the IGF system in the peripheral circulation and in follicles of varying sizes throughout the menstrual cycle in large numbers of subjects has been lacking. In the current study we performed daily IGF-I, IGF-II, IGFBP-1, and IGFBP-3 measurements in 9 ...

      Known for Menstrual Cycle | Binding Protein | Follicular Fluid | Growth Factor | Igfbp3 Levels
      KOL-Index: 18343

      A single injection of corifollitropin alfa can replace seven daily injections of recombinant FSH (rFSH) using a gonadotrophin-releasing hormone antagonist protocol in ovarian stimulation prior to IVF or intracytoplasmic sperm injection. This double-blind randomized controlled trial assessed the pharmacokinetics and pharmacodynamics of 150μg corifollitropin alfa versus daily 200IU rFSH in 1509 patients. Comparative analyses were performed on serum concentrations of FSH immunoreactivity ...

      Known for Ovarian Stimulation | Corifollitropin Alfa | Recombinant Fsh | Single Injection | Hormone Follicle
      KOL-Index: 17204

      BACKGROUND: The great majority of studies performed so far concerning women diagnosed with polycystic ovary syndrome (PCOS) have focused on diagnosis, menstrual cycle abnormalities, hirsutism and infertility. Although progress has been made in developing methods for achieving a pregnancy and reducing multiple gestations in women with PCOS, little attention has been paid to pregnancy complications and subsequent child outcomes. This review aims to summarize current knowledge regarding the ...

      Known for Pregnancy Complications | Women Pcos | Polycystic Ovary Syndrome | Spontaneous Diabetes | Longterm Health
      KOL-Index: 16853

      OBJECTIVE: To evaluate implantation and pregnancy rates in patients undergoing IVF after the transfer of a maximum of two embryos that had been cultured for 3-5 days.

      DESIGN: Prospective study.

      SETTING: An IVF laboratory at a tertiary referral university hospital.

      PATIENT(S): One thousand seven hundred eighty-seven couples who underwent their first IVF cycle between January 1995 and December 1997.

      INTERVENTION(S): In vitro fertilization and transfer of embryos after 3, 4, or 5 days of ...

      Known for Implantation Rates | Vitro Fertilization | Embryos Transfer | Embryo Culture | Blastocysts Day
      KOL-Index: 16280

      The present review describes, on the basis of the currently available evidence, the consensus reached by a group of experts on the use of gonadotropin-releasing hormone (GnRH) antagonists in ovarian stimulation for IVF. The single or multiple low-dose administration of GnRH antagonist during the late-follicular phase effectively prevents a premature rise in serum luteinizing hormone (LH) levels in most women. Although controversy remains, most comparative studies suggest a slight, not ...

      Known for Gnrh Antagonists | Ovarian Stimulation | Vitro Follicle | Pregnancy Ivf | Hormone Gonadotropin
      KOL-Index: 16008

      BACKGROUND: Here we describe the consensus guideline methodology, summarise the evidence-based recommendations we provided to the World Health Organisation (WHO) for their consideration in the development of global guidance and present a narrative review on the management of anovulatory infertility in women with polycystic ovary syndrome (PCOS).

      OBJECTIVE AND RATIONALE: The aim of this paper was to present an evidence base for the management of anovulatory PCOS.

      SEARCH METHODS: The ...

      Known for Anovulatory Infertility | Pcos Women | Ovulation Induction | Polycystic Ovary | Female Fertilization
      KOL-Index: 15945

      STUDY QUESTION: How does insulin action change during pregnancy in women with polycystic ovary syndrome (PCOS) who develop gestational diabetes (GDM) compared with women with PCOS who do not?

      SUMMARY ANSWER: Women with PCOS who develop GDM already show disturbed insulin action early in pregnancy.

      WHAT IS KNOWN ALREADY: Pregnant women with PCOS are at increased risk of developing GDM compared with women without PCOS.

      STUDY DESIGN, SIZE, DURATION: This study represents a post hoc analysis ...

      Known for Women Pcos | Gestational Diabetes | Polycystic Ovary Syndrome | Insulin Action | Conception Pregnancy
      KOL-Index: 15452

      STUDY QUESTION: What is the clinical value of anti-Müllerian hormone (AMH) for the prediction of high or low ovarian response in controlled ovarian stimulation for IVF using GnRH antagonist treatment?

      SUMMARY ANSWER: AMH as a single test has substantial accuracy for ovarian response prediction in GnRH antagonist treatment for IVF, with a higher accuracy for predicting a high response than for low response.

      WHAT IS KNOWN ALREADY: The role of AMH and other patient characteristics in ...

      Known for Ovarian Response | Gnrh Antagonist | Müllerian Hormone | Amh Prediction | Cycle Cancellation

      Key People For Ovarian Stimulation

      Top KOLs in the world
      #1
      Paul Devroey
      ovarian stimulation embryo transfer intracytoplasmic sperm injection
      #2
      Bart C J M FAUSER
      ovarian stimulation polycystic ovary syndrome vitro fertilization
      #3
      Rosenwaks Rosenwaks
      vitro fertilization embryo transfer intracytoplasmic sperm injection
      #4
      Basil C Tarlatzis
      ovarian stimulation vitro fertilization oocyte maturation
      #5
      Frank J M Broekmans
      ovarian reserve vitro fertilization ongoing pregnancy
      #6
      Herman J Tournaye
      embryo transfer intracytoplasmic sperm injection male infertility

      University of Utrecht, Utrecht, the Netherlands. | University Medical Center, 3584 Utrecht, the Netherlands. | University of Utrecht, Utrecht, The Netherlands | Department of Reproductive Medicine and Gynaecology, University Medical Center Utrecht, 3

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.